A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome
Conditions: Polycystic Ovary Syndrome (PCOS) Interventions: Other: lifestyle intervention; Device: acupuncture; Device: Sham acupuncture Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
Conditions: Ovarian Cancer Interventions: Behavioral: Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome
Conditions: Polycystic Ovarian Syndrome Interventions: Other: RADITIONAL MODERATE INTENSITY TRAINING; Other: HIGH INTENSITY INTERVAL TRAINING Sponsors: Riphah International University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Conditions: Ovary Neoplasm; Ovarian Cancer; Epithelial Ovarian Cancer; Recurrent Interventions: Biological: iC9-CAR.B7-H3 T cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: UNC Lineberger Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Conditions: Ovarian Cancer; Non-small Cell Lung Cancer Interventions: Drug: TUB-040 Sponsors: Tubulis GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Effects of HICT and Intermittent Fasting on PCOS
Conditions: Polycystic Ovary Syndrome; PCO Interventions: Other: High Intensity Circuit training (HICT); Other: Intermittent Fasting (IF); Other: Combination of HICT and IF Sponsors: Riphah International University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells
Conditions: Premature Ovarian Insufficiency Interventions: Procedure: autologous bone marrow cells injection Sponsors: abdulmajeed hammadi Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Activity of Chronic Inflammation in PCOS
Conditions: Polycystic Ovary Syndrome Interventions: Diagnostic Test: Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D; Diagnostic Test: Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters Sponsors: Jagiellonian University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma Interventions: Biological: NM32-2668 Sponsors: Numab Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer
Conditions: Ovarian Cancer Interventions: Other: Frailty and Quality of Life evaluation Sponsors: Sahar Salehi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers
Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma Interventions: Other: Non-Interventional Study Sponsors: University of Washington; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Conditions: Recurrent Ovarian Carcinoma Interventions: Procedure: Carboplatin or cisplatin; Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar; Drug: Bevacizumab or biosimilar; Procedure: Cytoreductive surgery Sponsors: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Inhibin B/AFC Ratio for Ovarian Response
Conditions: IVF; Infertility, Female; Ovulation Disorder Interventions: Drug: FSH-R Sponsors: Insemine Humen Reproduction Centre Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Conditions: Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Urothelial Carcinoma; Biliary Tract Cancer Interventions: Drug: BL-M07D1 Sponsors: SystImmune Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Mar. 5, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
